UBS Group’s LAVA Therapeutics LVTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-15,871
| Closed | -$24.8K | – | 10910 |
|
|
2025
Q3 | $24.8K | Sell |
15,871
-509
| -3% | -$760 | ﹤0.01% | 8022 |
|
|
2025
Q2 | $21.6K | Sell |
16,380
-515
| -3% | -$656 | ﹤0.01% | 8375 |
|
|
2025
Q1 | $21.5K | Sell |
16,895
-1,536
| -8% | -$1.71K | ﹤0.01% | 8187 |
|
|
2024
Q4 | $17.5K | Buy |
18,431
+17,359
| +1,619% | +$27.3K | ﹤0.01% | 7966 |
|
|
2024
Q3 | $1.78K | Buy |
+1,072
| New | +$1.96K | ﹤0.01% | 8555 |
|
|
2024
Q2 | – | Sell |
-8,980
| Closed | -$29.9K | – | 9859 |
|
|
2024
Q1 | $29.9K | Buy |
+8,980
| New | +$19.8K | ﹤0.01% | 6743 |
|
|
2023
Q2 | – | Sell |
-4,095
| Closed | -$6.8K | – | 9336 |
|
|
2023
Q1 | $6.8K | Buy |
4,095
+3,094
| +309% | +$8.66K | ﹤0.01% | 7882 |
|
|
2022
Q4 | $3.5K | Buy |
+1,001
| New | +$4.59K | ﹤0.01% | 9500 |
|
|
2022
Q3 | – | Sell |
-406
| Closed | -$1K | – | 10681 |
|
|
2022
Q2 | $1K | Sell |
406
-820
| -67% | -$2.84K | ﹤0.01% | 9903 |
|
|
2022
Q1 | $5K | Sell |
1,226
-523
| -30% | -$2.66K | ﹤0.01% | 9140 |
|
|
2021
Q4 | $10K | Buy |
+1,749
| New | +$11.5K | ﹤0.01% | 8787 |
|
UBS Group's LVTX Position: Q4 2025 in Review
UBS Group sold out of LAVA Therapeutics (LVTX) in Q4 2025, closing a stake of 15,871 shares — an estimated $24.8K sold.
UBS Group first reported a position in LVTX in Q4 2021 and held it in 11 quarters. The position peaked at $29.9K in Q1 2024. 0 funds tracked by Wall St. Rank hold LVTX as of Q4 2025.
- UBS Group reported no remaining LAVA Therapeutics position as of Q4 2025 after selling out during the quarter.
- UBS Group sold 15,871 LAVA Therapeutics shares in Q4 2025, an estimated $24.8K.
- UBS Group first reported a position in LAVA Therapeutics in Q4 2021 and held it in 11 quarters.
- UBS Group's LAVA Therapeutics position peaked at $29.9K in Q1 2024.
- 0 funds tracked by Wall St. Rank held LAVA Therapeutics as of Q4 2025.
Based on UBS Group's 13F filing for Q4 2025, filed 29 Jan 2026.